The Society for Cardiovascular Angiography & Interventions’ (SCAI’s) position statement on renal denervation comes at a “critical time” in the development of the treatment, and aims to provide “much needed guidance” for physician operators who may be seeking to deploy the therapy.
This is according to Herbert Aronow (Henry Ford Health, Detroit, USA and Michigan State University College of Human Medicine, East Lansing, USA), chair of the writing group that formulated the statement, published in the Journal of the Society for Cardiovascular Angiography & Interventions (JSCAI) this week.
“In anticipation of FDA approval for renal denervation this is really a critical time and SCAI is playing a key role in efforts to guide physician operators and to guide facilities on how to go about bringing this technology forward,” told Cardiovascular News.
In the interview, Aronow comments that even if US Food and Drug Administration (FDA) approval is granted in “just a fraction” of the population of adults with hypertension, it has the potential to become a fairly commonly encountered procedure. Aronow also comments on the important factors for decision making when weighing up the therapy, including the importance of patient preference and shared decision-making.
